Clinical Specialties & Body Systems

Deep dives by specialty—organs, systems, and diseases managed by expert teams.

  • 16 Subtopics
  • 5 Tracked terms
  • Last 30 days Feed window
Search within this topic Ask AI about this topic All topics

Inside Clinical Specialties & Body Systems

Cardiology & Metabolic Health Heart disease, hypertension, lipids, diabetes, and metabolic syndrome. Oncology & Hematology Cancer prevention, screening, therapies, survivorship, and blood disorders. Neurology & Neuroscience Stroke, migraine, epilepsy, neurodegeneration, and movement disorders. Orthopedics & Sports Medicine Bones, joints, tendons; injuries, imaging, and surgical/rehab options. Respiratory & Pulmonology Asthma, COPD, sleep apnea, infections, and environmental lung risks. Gastroenterology & Hepatology Gut health, IBD/IBS, reflux, liver disease, and microbiome research. Endocrinology & Hormones Thyroid, adrenal, reproductive hormones, and metabolic disorders of glands. Nephrology & Urology Kidneys, dialysis, stones, infections, prostate, and continence concerns. Dermatology Skin cancer checks, eczema/psoriasis, acne care, and cosmetic dermatology news. Rheumatology & Autoimmune Arthritis, lupus, vasculitis, biologics, and immune‑modulating therapies. OB‑GYN (Women’s Health) Reproductive health, pregnancy, menopause, and gynecologic care advances. Pediatrics & Adolescent Health Well‑child care, vaccinations, development, and school health issues. Geriatrics & Healthy Aging Falls, cognition, polypharmacy, frailty, and independence strategies. Ophthalmology & Vision Glaucoma, cataracts, macular degeneration, and eye‑care technology updates. ENT (Ear, Nose & Throat) Hearing loss, sinus and allergy care, voice, and sleep‑related airway issues. Dentistry & Oral Health Preventive dentistry, periodontal disease, orthodontics, and oral surgery care.

What this topic collects on

An article joins this feed when it matches these terms. Each one is also a search of its own.

Latest in Clinical Specialties & Body Systems


postandcourier.com > moultrie-news > news > leaders-advocate-for-health-and-fighting-heart-disease > article_2725b574-746a-437a-9b21-424660278e16.html

Fantastic Four: Leaders advocate for health and fighting heart disease

54+ min ago   (318+ words) Four Charleston-area leaders are joining the American Heart Association’s Leaders of Impact™ campaign, a seven-week initiative to raise awareness and funds to prevent cardiovascular disease, the leading cause of death nationwide. More than 61 percent of the US population is expected…...


techbullion.com > dr-cory-torgerson-of-the-toronto-hair-transplant-clinic-introduces-combined-fue-prp-and-laser-phototherapy-protocol-to-preserve-native-hair-density

Dr. Cory Torgerson of The Toronto Hair Transplant Clinic Introduces Combined FUE, PRP, and Laser Phototherapy Protocol to Preserve Native Hair Density

45+ min ago   (26+ words) Density requirements are set for the different recipient zones with individual hair grafts at the hairline edge and multi-hair grafts in the mid-scalp and crown zone....


medicaldialogues.in > pulmonology > news > vtd-shows-potential-to-modify-cystic-fibrosis-progression-in-young-children-study-179213

VTD Shows Potential to Modify Cystic Fibrosis Progression in Young Children: Study

4+ hour, 9+ min ago   (54+ words) Ten Years to Dapagliflozin Metformin FDC Approval in India - 10 Key Points to Revisit Overcoming the Challenge of Maintaining Weight Reduction Sympathetic Overactivity: The Driver of Hypertension in Young Indians India's Medical Startups: From Innovation to Impact - Prof. (Dr) Yogendra Kumar…...


markets.businessinsider.com > news > stocks > santa-ana-bio-announces-first-subjects-dosed-in-phase-1-study-of-sab01-to-treat-autoimmune-inflammatory-diseases-1036542739

Santa Ana Bio Announces First Subjects Dosed in Phase 1 Study of SAB01 to Treat Autoimmune Inflammatory Diseases

18+ hour, 45+ min ago   (402+ words) First-in-class bispecific antibody designed for mast cell elimination without the safety issues associated with current KIT therapeuticsPhase 1 si... Santa Ana Bio Announces First Subjects Dosed in Phase 1 Study of SAB01 to Treat Autoimmune Inflammatory Diseases - First-in-class bispecific antibody designed for mast…...


dvidshub.net > news > 574635 > ntag-mid-america-sailors-support-national-blood-supply-across-four-state-aor

NTAG Mid America Sailors Support National Blood Supply Across Four-State AOR

1+ hour, 19+ min ago   (0+ words) ...


abccolumbia.com > 09/14/2026 > cdc-warns-of-increasing-rabies-exposures

CDC warns of increasing rabies exposures

1+ hour, 55+ min ago   (114+ words) (CNN)– The CDC is warning that rabies exposures appear to be rising across the U.S. The agency says it received 17% more rabies-related inquiries in July and August than during the same period last year. At least 8 state health departments have…...


prevention.com > health > a73/72/3682 > rabies-vaccine-cdc-health-alert

5 Things to Know About the Rabies Vaccine After CDC Issues Alert

2+ hour, 43+ min ago   (1110+ words) It’s no longer given in the stomach, for starters. The Centers for Disease Control and Prevention (CDC) has issued a health alert after an increase in reports of exposure to rabid or possibly rabid animals in the U.S. The alert…...


bbc.co.uk > programmes > l0058vch

BBC News - New Treatment Gives Hope to People with Ovarian Cancer

1+ day, 2+ hour ago   (59+ words) The former nurse, who was told her stage four ovarian cancer was inoperable, is now cancer-free, thanks to a pioneering new treatment developed in Southampton. New Treatment Gives Hope to People with Ovarian Cancer The former nurse, who was told…...


medium.com > @eabensonresearchcentre > how-to-do-better-research-a-practical-guide-for-medical-and-community-medicine-researchers-f7da06985445

How to Do Better Research: A Practical Guide for Medical and Community Medicine Researchers

7+ hour, 42+ min ago   (1192+ words) From a Good Research Question to Meaningful Evidence By Dr. Shamin Eabenson, MBBS, MD Community …...


natlawreview.com > press-releases > enhertur-demonstrated-median-progression-free-survival-143-months-first-line

Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial

16+ hour, 17+ min ago   (848+ words) Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). In the primary endpoint analysis, Enhertu monotherapy significantly reduced…...